 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Lynn Heasley and Tejas Patil.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.953 |
|
|
|
-
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T. High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors. Clin Lung Cancer. 2026 Apr 30.
Score: 0.248
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Avila JT, Skhisov D, Haines S, Navarro AC, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. Cancer Lett. 2026 Jun 28; 648:218467.
Score: 0.247
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Haines S, Navarro A, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. bioRxiv. 2025 Jun 07.
Score: 0.233
-
Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021 May 17; 5(1):41.
Score: 0.176
-
Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. NPJ Precis Oncol. 2023 Feb 04; 7(1):15.
Score: 0.050
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|